State Key Laboratory of Medical Neurobiology, Shanghai Medical College and Institutes of Brain Science, Fudan University, Shanghai, China.
Ann Neurol. 2013 Feb;73(2):189-98. doi: 10.1002/ana.23762. Epub 2012 Dec 31.
Tissue plasminogen activator (tPA) is approved for treatment of acute ischemic stroke, but it increases the risk of cerebral hemorrhage. Accumulating evidence suggests that von Willebrand factor (VWF) plays a pivotal role in thrombus formation and microcirculatory disturbances after ischemic stroke. By cleaving VWF, ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) protects mice from stroke. Therefore, we hypothesized that recombinant ADAMTS13 (rADAMTS13) could increase the safety of tPA thrombolysis in stroke.
We examined blood-brain barrier (BBB) permeability after intraventricular injection of tPA, VWF, and rADAMTS13 in nonischemic mice. We investigated the role of rADAMTS13 on reducing tPA-induced BBB dysfunction and cerebral hemorrhage in a mouse stroke model.
Intraventricular injection of tPA or VWF under nonischemic conditions resulted in a significant increase in BBB permeability. In contrast, rADAMTS13 blocked both tPA- and VWF-induced BBB opening. BBB disruption following stroke was exacerbated by intravenous administration of tPA, but this was attenuated by injection of rADAMTS13. Correspondingly, tPA-associated hemorrhage after stroke was significantly reduced by rADAMTS13. The antihemorrhagic effect of rADAMTS13 was reversed by injection of recombinant VWF. We also showed that rADAMTS13 inhibited tPA-mediated upregulation of vascular endothelial growth factor (VEGF) in vascular endothelium after stroke. The upregulation of VEGF was suppressed by either an Akt inhibitor wortmannin or a Rho kinase inhibitor fasudil. Furthermore, rADAMTS13 downregulated tPA-induced phosphorylation of Akt and activation of RhoA.
These findings demonstrate that the VWF-cleaving protease rADAMTS13 reduced tPA-induced hemorrhage by regulating BBB integrity, and suggest that this effect may occur through the Akt/RhoA-mediated VEGF pathways.
组织型纤溶酶原激活物(tPA)已被批准用于治疗急性缺血性脑卒中,但它会增加脑出血的风险。越来越多的证据表明,血管性血友病因子(VWF)在缺血性脑卒中后血栓形成和微循环障碍中发挥关键作用。ADAMTS13(一种带有血小板反应蛋白 1 型基序的解整合素金属蛋白酶 13)通过切割 VWF 来保护小鼠免受脑卒中的影响。因此,我们假设重组 ADAMTS13(rADAMTS13)可以增加 tPA 溶栓治疗脑卒中的安全性。
我们在非缺血性小鼠的侧脑室注射 tPA、VWF 和 rADAMTS13 后,检测血脑屏障(BBB)通透性。我们研究了 rADAMTS13 对减少 tPA 诱导的 BBB 功能障碍和脑出血的作用。
非缺血条件下侧脑室注射 tPA 或 VWF 会导致 BBB 通透性显著增加。相比之下,rADAMTS13 阻断了 tPA 和 VWF 诱导的 BBB 开放。在脑卒中后,静脉内给予 tPA 会加剧 BBB 破坏,但 rADAMTS13 的注射会减轻这种破坏。相应地,rADAMTS13 显著减少了脑卒中后与 tPA 相关的出血。rADAMTS13 的抗出血作用在注射重组 VWF 后被逆转。我们还表明,rADAMTS13 抑制了脑卒中后血管内皮细胞中 tPA 介导的血管内皮生长因子(VEGF)的上调。Akt 抑制剂渥曼青霉素或 Rho 激酶抑制剂法舒地尔抑制了 VEGF 的上调。此外,rADAMTS13 下调了 tPA 诱导的 Akt 磷酸化和 RhoA 的激活。
这些发现表明,VWF 切割蛋白酶 rADAMTS13 通过调节 BBB 完整性减少了 tPA 诱导的出血,并表明这种作用可能通过 Akt/RhoA 介导的 VEGF 途径发生。